Yes-Associated Protein and Transcriptional Coactivator with PDZ-Binding Motif in Cardiovascular Diseases

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Jan 21

PMID 36675179

Authors

Ruojun Li

Weiqiang Huang

Affiliations

Soon will be listed here.

Abstract

Yes-associated protein (YAP, also known as YAP1) and its paralogue TAZ (with a PDZ-binding motif) are transcriptional coactivators that switch between the cytoplasm and nucleus and regulate the organ size and tissue homeostasis. This review focuses on the research progress on YAP/TAZ signaling proteins in myocardial infarction, cardiac remodeling, hypertension and coronary heart disease, cardiomyopathy, and aortic disease. Based on preclinical studies on YAP/TAZ signaling proteins in cellular/animal models and clinical patients, the potential roles of YAP/TAZ proteins in some cardiovascular diseases (CVDs) are summarized.

Citing Articles

YAP/TAZ as mechanobiological signaling pathway in cardiovascular physiological regulation and pathogenesis.

Islam R, Hong Z Mechanobiol Med. 2024; 2(4).

PMID: 39281415 PMC: 11391866. DOI: 10.1016/j.mbm.2024.100085.

References

Fu M, Hu Y, Lan T, Guan K, Luo T, Luo M . The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Target Ther. 2022; 7(1):376. PMC: 9643504. DOI: 10.1038/s41392-022-01191-9. View

Lin Z, Guo H, Cao Y, Zohrabian S, Zhou P, Ma Q . Acetylation of VGLL4 Regulates Hippo-YAP Signaling and Postnatal Cardiac Growth. Dev Cell. 2016; 39(4):466-479. PMC: 5121000. DOI: 10.1016/j.devcel.2016.09.005. View

Kim T, Hwang D, Lee D, Kim J, Kim S, Lim D . MRTF potentiates TEAD-YAP transcriptional activity causing metastasis. EMBO J. 2016; 36(4):520-535. PMC: 5694947. DOI: 10.15252/embj.201695137. View

Leong D, Joseph P, Mckee M, Anand S, Teo K, Schwalm J . Reducing the Global Burden of Cardiovascular Disease, Part 2: Prevention and Treatment of Cardiovascular Disease. Circ Res. 2017; 121(6):695-710. DOI: 10.1161/CIRCRESAHA.117.311849. View

Allaire E, Schneider F, Saucy F, Dai J, Cochennec F, Michineau S . New insight in aetiopathogenesis of aortic diseases. Eur J Vasc Endovasc Surg. 2009; 37(5):531-7. DOI: 10.1016/j.ejvs.2009.02.002. View

Qi S, Zhu Y, Liu X, Li P, Wang Y, Zeng Y . WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy. Mol Cell. 2022; 82(10):1850-1864.e7. DOI: 10.1016/j.molcel.2022.03.027. View

Chen S, Gurha P, Lombardi R, Ruggiero A, Willerson J, Marian A . The hippo pathway is activated and is a causal mechanism for adipogenesis in arrhythmogenic cardiomyopathy. Circ Res. 2013; 114(3):454-68. PMC: 3946717. DOI: 10.1161/CIRCRESAHA.114.302810. View

Kim J, Kim Y, Kim J, Park D, Bae H, Lee D . YAP/TAZ regulates sprouting angiogenesis and vascular barrier maturation. J Clin Invest. 2017; 127(9):3441-3461. PMC: 5669570. DOI: 10.1172/JCI93825. View

Yimlamai D, Christodoulou C, Galli G, Yanger K, Pepe-Mooney B, Gurung B . Hippo pathway activity influences liver cell fate. Cell. 2014; 157(6):1324-1338. PMC: 4136468. DOI: 10.1016/j.cell.2014.03.060. View

10.

Xin M, Kim Y, Sutherland L, Murakami M, Qi X, McAnally J . Hippo pathway effector Yap promotes cardiac regeneration. Proc Natl Acad Sci U S A. 2013; 110(34):13839-44. PMC: 3752208. DOI: 10.1073/pnas.1313192110. View

11.

Lorthongpanich C, Thumanu K, Tangkiettrakul K, Jiamvoraphong N, Laowtammathron C, Damkham N . YAP as a key regulator of adipo-osteogenic differentiation in human MSCs. Stem Cell Res Ther. 2019; 10(1):402. PMC: 6921580. DOI: 10.1186/s13287-019-1494-4. View

12.

Gibault F, Sturbaut M, Bailly F, Melnyk P, Cotelle P . Targeting Transcriptional Enhanced Associate Domains (TEADs). J Med Chem. 2017; 61(12):5057-5072. DOI: 10.1021/acs.jmedchem.7b00879. View

13.

Choi H, Kim N, Kim B, Seo M, Heo J . TNF-α-Induced YAP/TAZ Activity Mediates Leukocyte-Endothelial Adhesion by Regulating VCAM1 Expression in Endothelial Cells. Int J Mol Sci. 2018; 19(11). PMC: 6274800. DOI: 10.3390/ijms19113428. View

14.

Foster C, Gualdrini F, Treisman R . Mutual dependence of the MRTF-SRF and YAP-TEAD pathways in cancer-associated fibroblasts is indirect and mediated by cytoskeletal dynamics. Genes Dev. 2018; 31(23-24):2361-2375. PMC: 5795783. DOI: 10.1101/gad.304501.117. View

15.

Heng B, Zhang X, Aubel D, Bai Y, Li X, Wei Y . An overview of signaling pathways regulating YAP/TAZ activity. Cell Mol Life Sci. 2020; 78(2):497-512. PMC: 11071991. DOI: 10.1007/s00018-020-03579-8. View

16.

Zanconato F, Forcato M, Battilana G, Azzolin L, Quaranta E, Bodega B . Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol. 2015; 17(9):1218-27. PMC: 6186417. DOI: 10.1038/ncb3216. View

17.

Seo E, Basu-Roy U, Gunaratne P, Coarfa C, Lim D, Basilico C . SOX2 regulates YAP1 to maintain stemness and determine cell fate in the osteo-adipo lineage. Cell Rep. 2013; 3(6):2075-87. PMC: 5053763. DOI: 10.1016/j.celrep.2013.05.029. View

18.

Devereux R, Roman M, Paranicas M, OGrady M, Lee E, Welty T . Impact of diabetes on cardiac structure and function: the strong heart study. Circulation. 2000; 101(19):2271-6. DOI: 10.1161/01.cir.101.19.2271. View

19.

Venugopal H, Hanna A, Humeres C, Frangogiannis N . Properties and Functions of Fibroblasts and Myofibroblasts in Myocardial Infarction. Cells. 2022; 11(9). PMC: 9102016. DOI: 10.3390/cells11091386. View

20.

Cunningham R, Hansen C . The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer. Clin Sci (Lond). 2022; 136(3):197-222. PMC: 8819670. DOI: 10.1042/CS20201474. View